Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002909 · ClinicalTrials.gov registry record · Phase 1

Phenylbutyrate in Treating Patients With Refractory Solid Tumors or Lymphoma

A Phase 1 study, sponsored by National Cancer Institute (NCI).

Completed
Registry status
Phase 1
Development phase
24
Enrollment target

NCT00002909: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).

NCT00002909 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 24 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add start date to calendar (.ics) →

The verdict

NCT00002909, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).

COMPLETED
Registry status
Phase 1
Development phase
24 participants
Enrollment target

Study Summary

Phase I trial to study the effectivenes of phenylbutyrate in treating adults with refractory solid tumor or lymphoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

Interventions

  • DRUG chemotherapy
  • DRUG oral sodium phenylbutyrate

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 1997-02
Phase Phase 1
National Cancer Institute (NCI)

3,257 total trials

What the finished NCT00002909 record still lists

NCT00002909 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower).

The record links to 0 conditions, and to 2 interventions - of which chemotherapy is the first listed.

NCT00002909 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00002909 about?

NCT00002909 is a clinical study titled "Phenylbutyrate in Treating Patients With Refractory Solid Tumors or Lymphoma". Phase I trial to study the effectivenes of phenylbutyrate in treating adults with refractory solid tumor or lymphoma. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

What is the current status of trial NCT00002909?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 1997-02.

What interventions are being tested in trial NCT00002909?

The interventions under investigation include: chemotherapy (DRUG), oral sodium phenylbutyrate (DRUG).

Who is sponsoring clinical trial NCT00002909?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00002909's enrollment target sits among peer trials

24 1520th of 2000 higher than 405 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00002909, the US trial registry maintained by the National Library of Medicine. NCT00002909 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.